Linifanib is a potent receptor tyrosine kinase (RTK) inhibitor. It inhibits PDGFRβ, KDR, FLT3, CSF-1R (IC50 values are 2, 4, 4 and 7 nM, respectively). Linifanib inhibits angiogenesis in vascularized micro-organs and potently inhibits VEGF-stimulated endothelial cell proliferation (IC50 = 0.2 nM). Linifanib also promotes the generation and reprogramming of iPSCs from somatic cells.
Caractéristiques techniques
| Marque | Tocris Bioscience |
|---|
| Réf. B-LABO | BL-RE-124727 |
|---|
| Réf. fabricant | 18799036 |
|---|
| Nom chimique ou matériau | N-[4-(3-Amino-1 H-indazol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea |
|---|
| CAS | 796967-16-3 |
|---|
| Quantité | 50 mg |
|---|
| Cible | PDGF R beta |
|---|
| Formule moléculaire | C<sub>21</sub>H<sub>18</sub>FN<sub>5</sub>O |
|---|
| Pureté | 0.98 |
|---|
Une question, une configuration particulière ?
Contactez-nous pour un devis.
